Search Results
11 results found-
Denteric is developing a therapeutic vaccine for the one billion people (one third of all adults) globally suffering from periodontal gum disease - a disease that is also associated with diabetes, heart disease, rheumatoid arthritis, dementia, and certain cancers.
https://newsroom.csl.com/2024-04-18-Jumar-Bioincubator-Release -
CSL, one of Jumar’s founding partners, celebrated the launch of the state-of-the-art facility, designed to help early-stage biotech innovators make discoveries that will help patients.
https://www.csl.com/we-are-csl/vita-original-stories/2024/jumar-bioincubator-opens-in-melbourne-australia -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note_2022_ch.pdf -
Did you know? More than 25 percent of U.S. adults have two or more health conditions.
https://www.csl.com/we-are-csl/vita-original-stories/2022/what-are-comorbidities -
The complex immune system weakens over time and becomes less able to defend the body from infection and illness, but older people can shore it up with healthy habits.
https://www.csl.com/we-are-csl/vita-original-stories/2023/how-the-immune-system-changes-as-you-age -
10 early-career scientists will receive $20,000 grants from Uplifting Athletes to further their research into new treatments that will benefit patients who live with rare conditions.
https://www.csl.com/we-are-csl/vita-original-stories/2023/drafting-a-new-class-of-rare-disease-researchers -
Eblasakimab (Anti-IL-13R mAb) Atopic Dermatitis Mavrilimumab (Anti-GM-CSFR mAb) Giant Cell Arteritis, Rheumatoid Arthritis** *
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2021-22.pdf -
This means information that a reasonable person would expect to have a material effect on the price or value of CSL's securities, being any information that would, or would be likely to, influence persons who commonly invest in securities in deciding whether or not to subscribe for, buy or sell those securities.
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/continuous-disclosure-policy.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-romania-2021.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-ireland-2021.pdf